The Efficiency of Daptomycin Use in Treatment of Surgical Patients with Infective Endocarditis

Abstract


Relevance This purpose of the study was to evaluate the efficacy of daptomycin therapy in surgical patients with infective endocarditis.
Materials and methods The cohort included 39 patients with active infective endocarditis. For antimicrobial treatment, daptomycin was used as monotherapy in 7 patients (group 1); 13 patients received daptomycin in combination with other antibiotics (group 2); in 19 patients other antibiotics were used (group 3). 35 patients had undergone valve surgery with CPB. The demographic, clinical, microbiological, echocardiographic and laboratory data was analyzed.
Results and their discussion In-hospital mortality in general cohort was 18.0%. in the group of patients with daptomycin monotherapy it was 14.3%; patients treated with daptomycin in combination with other antibiotics it was 23.1%; and in patients treated with other antimicrobial agents it was 15.8%. Overall surgical mortality was 14.3%. Criteria for successful treatment were identified in 28 (71.8%) patients: in 6 (85.7%) patients in group 1; in 9 (69.2%) patients in group 2, and in 13 (68.4%) in group 3. The analysis of the laboratory data has shown that preoperative patients in Groups 1 and 2 had more pronounced multiple organ failure in comparison with patients from group 3. In postoperative period, no differences in severity of multiple organ failure markers in groups was determined.
Conclusion The use of daptomycin in perioperative treatment of patients with infective endocarditis was characterized by a high percentage of positive effect of treatment results. In surgical patients with infective endocarditis, complicated by severe multi-organ failure, the use of daptomycin is expedient and leads to the normalization of laboratory parameters.

Voronezh State Regional Clinical Hospital, 151 Moskovskii Ave., Voronezh, 394066, Russian Federation N.N. Burdenko Voronezh State Medical University, 10 Studencheskaia Str., Voronezh, 394036,Russian Federation

Author for correspondence.
Email: sakovalev61@gmail.com
MD, Prof. of Hospital Surgery Chair N.N. Burdenko Voronezh State Medical University. The Head of Cardiac Surgery Department №1, The Head of Voronezh Cardiac Surgery Center, Chief Cardiovascular Surgeon of Voronezh Region

Voronezh State Regional Clinical Hospital, 151 Moskovskii Ave., Voronezh, 394066, Russian Federation N.N. Burdenko Voronezh State Medical University, 10 Studencheskaia Str., Voronezh, 394036,Russian Federation

Email: dgryaznov@hotmail.com
PhD, Assistant Prof. of Hospital Surgery Chair N.N. Burdenko Voronezh State Medical University. Cardiovascular Surgeon of Department of Cardiac Surgery №1 of Voronezh State Regional Clinical Hospital

N.N. Burdenko Voronezh State Medical University, 10 Studencheskaia Str., Voronezh, 394036, Russian Federation

Email: eakvrn@gmail.com
clinical intern of Hospital Surgery Chair N.N. Burdenko Voronezh State Medical University

Voronezh State Regional Clinical Hospital, 151 Moskovskii Ave., Voronezh, 394066, Russian Federation

Email: zavatskysv@gmail.com
cardiovascular Surgeon of Department of Cardiac Surgery №1 Voronezh State Regional Clinical Hospital

N.N. Burdenko Voronezh State Medical University, 10 Studencheskaia Str., Voronezh, 394036, Russian Federation

Email: panteradoc666@gmail.com
clinical intern of Hospital Surgery Chair N.N. Burdenko Voronezh State Medical University

  • Gel'fand E.B., Tselenzhapov E.Ts., Karabak V.I. et al. Meropenem ehffektiven v lechenii abdominal'nogo sepsisa u hirurgicheskih bol'nyh [Meropenem effective in treatment of abdominal sepsis in surgical patients]. Antibiotiki i khimioterapiia, 2000; 45: 5: 27–32. - (in Russ.).
  • Dekhnich A.V., Danilov A.I. Obzor farmakologicheskih, klinicheskih i mikrobiologicheskih parametrov. [Overview of pharmacological, clinical and microbiological parameters]. Klinicheskaia mikrobiologiia i antimikrobnaia khimioterapiia, 2010; 12:4: 295–313. - (in Russ.).
  • Popov D.A., Vostrikova T.Iu. Mikrobiologicheskij monitoring v kardiohirurgicheskom otdelenii - 10 let praktiki [Microbiological monitoring in cardio surgical department – 10 years practice]. Biulleten' NTsSSKh im. A.N. Bakuleva RAMN Serdechno-sosudistye zabolevaniia [Bulletin of A.N. Bakulev NTSSK. Cardiovascular diseases], 2012; 13: 5: 68-76. - (in Russ.).
  • Rudnov V.A., Bel'skii D.V., Dekhnich A.V. Infekcii v otdelenii intensivnoj terapii i reanimatologii: rezul'taty nacional'nyh mnogocentrovyh issledovanij [Infections in intensive therapy and reanimatology: results of national multicentral research]. Klinicheskaia mikrobiologiia antimikrobnoi khimioterapii, 2011; 13:4: 294–303. - (in Russ.).
  • Popov D.A. Posleoperacionnye infekcionnye oslozhneniya v kardiohirurgii. [Postoperative infective complications in cardiosurgery]. Annaly khirurgii, 2013; 5: 15–21. - (in Russ.).
  • Tiurin V.P., Serdiuk I.E., Kushenko I.P., Lashenkova N.N., Gaidukova I.A. Rol' i mesto daptomicina v terapii infekcionnogo ehndokardita [Daptomycin’s role and place in infective endocarditis therapy]. Klinicheskaia meditsina, 2012; 90: 4: 63-66. - (in Russ.).
  • Sidorenko S.V., Rezvan S.P. et al. Sravnitel'naya ocenka meropenema i drugih antibiotikov v otnoshenii vozbuditelej vnutribol'nichnyh infekcij. [Comparative evaluation of meropenem and other antibiotics against pathogens of nosocomial infections]. Antibiotiki i khimioterapiia, 1998; 43: 1: 4–14. - (in Russ.).
  • Kotova E.O., Karaulova Iu.L., Borisov I.A., Ezhova L.G. EHffektivnost' i bezopasnost' daptomicin v lechenii grampolozhitel'nyh infekcij, vklyuchaya infekcionnyj ehndokardit. [The efficacy and safety of daptomycin in the treatment of Gram-positive infections, including infective endocarditis]. Klinicheskaia farmakologiia i terapiia, 2013; 22: 2: 67–73. - (in Russ.).
  • Strachunskii L.S., Kozlov R.S., Stetsiuk O.U., Rozenson O.L. Problema vybora karbopenemnyh antibiotikov. [Problem of choosing karbapenemic antibiotics.] Klinicheskaia farmakologiia i terapiia, 1997; 6: 4: 59–62. - (in Russ.).
  • Tiurin V.P. Infektsionnye endokardity: rukovodstvo [Infective endocarditis: guidelines]. Moscow: GEOTAR–Med., 2012; 368. - (in Russ.).
  • Iakovlev S.V. Klinicheskaia khimioterapiia bakterial'nykh infektsii [Clinical therapy of bacterial infections]. Moscow, 1997; 148. - (in Russ.).
  • Seiidov V.G., Andriukov B.G. Sovremennye prichinnaya diagnostika i racional'naya antibakterial'naya terapiya infekcionnogo ehndokardita. [Modern causal diagnosis and rational antibiotic therapy of infective endocarditis.] Klinicheskaia farmakologiia i terapiia, 2012; 21:3: 78-81. - (in Russ.).
  • Shcheka D.V., Iakovlev S.V. Sovremennye klinicheskie osobennosti i lechenie antibiotikami stafilokokkovogo infekcionnogo ehndokardita. [Modern clinical features and antibiotic treatment of staphylococcal infective endocarditis]. Klinicheskaia farmakologiia i terapiia, 2008: 17:2: 32-36. - (in Russ.).
  • Becky McCall. Sepsis Cure Rate With Daptomycin Up to 85%. 22nd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). 2012 Apr 2. Posters 1844, 1845 and 1846.
  • Byrne JG, Rezai K, Sanchez JA, et al. Surgical Management of Endocarditis: The Society of Thoracic Surgeons Clinical Practice Guideline. Ann. Thorac. Surg., 2011; 91: 2012–19.
  • Chirouze C., Athan E., Alla F., Chu V.H., et al. Enterococcal endocarditis in the beginning of the 21st century: analysis from the International Collaboration on Endocarditis-Prospective Cohort Study. Clinical Microbiology and Infection, 2013; 19:12: 1140– 47.
  • Delinger R.P., Levy M.M., Rhodes A., et al: Surviving Sepsis Campaign: International Guidelunes for Management of Severe Sepsis and Septic Shock: 2012. Crit. Care. Med, 2013; 41: 580–637.
  • Fowler V.G. Jr , Boucher H.W., Corey G.R. et al. for the S. aureus Endocarditis and Bacteremia Study Group. Daptomycin versus Standard Therapy for Bacteremia and Endocarditis Caused by Staphylococcus aureus. N. Engl. J. Med., 2006; 355: 653–65.
  • Jung D., Rosek A., Okon M., Hancock R.E. Structural transition as determinants of the action of the calcium-dependent antibiotic daptomycin. Chem. Biol., 2004; 11:949–57.
  • Kumar A, Zarychanski R, et al. Combination antimicrobial therapy yields improved survival compared to monotherapy in septic shock: A propensity-matched analysis. Critical Care Medicine, 2010; 38: 1773–85.
  • Watkin R., Sandoe J. British society of antimicrobial chemotherapy (bsac) guidelines for the diagnosis and treatment of endocarditis: what the cardiologist needs to know. Heart (British Cardiac Society), 2012; 98:10: 757-759.
  • Pfaller M.A., Sader H.S., Jones R.N. Evaluation of the in vitro activity of daptomycin against 19615 clinical isolates of Gram-positive cocci collected in North America hospitals(2002-2005). Diaga Microbial Infect. Dis., 2007; 55: 459–65.
  • Rege S., Mohr J., Lamp K.C., Yoon M., Lindfield K.C. Safety of daptomycin in patients completing more than 14 days of therapy: results from the Cubicin® Outcomes Registry and experience. Int. J. Antimicrob. Agents, 2013; 41(5): 421–5.
  • V. G. Mishalov, L. Yu. Markulan, A. A. Burka, S. M. Goyda, S.M. Vamush: Сombined (cefepime and metronidazole) antibiotic therapy effectiveness in the treatment of complicated intra-abdominal infections. Ukraine surgery “VIT-A-POL”, 2014, 2:55.
  • Wiseman L.R., Wagstaff A.J., Bergden R.N. et al. Меrореnem. Rеview. Drugs, 1995; 50: 1: 73–101.

Views

Abstract - 57

PDF (Russian) - 44

PlumX


Copyright (c) 2015 ., ., ., ., .

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.